182 related articles for article (PubMed ID: 37098494)
1. A phase 2 study of stereotactic body radiation therapy for squamous cell carcinoma of the head and neck (SHINE): a single arm clinical trial protocol.
Lee J; Nguyen NT; Wright J; Yeung KD; Sagar S; Kim DH; Ostapiak O; Doerwald-Munoz L; Whelan T
BMC Cancer; 2023 Apr; 23(1):379. PubMed ID: 37098494
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.
Spaas M; Sundahl N; Hulstaert E; Kruse V; Rottey S; De Maeseneer D; Surmont V; Meireson A; Brochez L; Reynders D; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Mestdagh P; Ost P
BMC Cancer; 2021 May; 21(1):514. PubMed ID: 33962592
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck.
Echevarria MI; Yang GQ; Chen DT; Kirtane K; Russell J; Kish J; Muzaffar J; Otto K; Padhya T; McMullen C; Patel K; Chung CH; Caudell JJ
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):341-347. PubMed ID: 37105404
[TBL] [Abstract][Full Text] [Related]
8. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
Rwigema JC; Heron DE; Ferris RL; Andrade RS; Gibson MK; Yang Y; Ozhasoglu C; Argiris AE; Grandis JR; Burton SA
Am J Clin Oncol; 2011 Aug; 34(4):372-9. PubMed ID: 20859194
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
Siddiqui F; Patel M; Khan M; McLean S; Dragovic J; Jin JY; Movsas B; Ryu S
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1047-53. PubMed ID: 19327895
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series.
Kress MA; Sen N; Unger KR; Lominska CE; Deeken JF; Davidson BJ; Newkirk KA; Hwang J; Harter KW
Head Neck; 2015 Oct; 37(10):1403-9. PubMed ID: 24824359
[TBL] [Abstract][Full Text] [Related]
11. The role of stereotactic body radiotherapy in reirradiation of head and neck cancer recurrence.
Román A A; Jodar C; Perez-Rozos A; Lupiañez-Perez Y; Medina JA; Gomez-Millan J
Crit Rev Oncol Hematol; 2018 Feb; 122():194-201. PubMed ID: 29373181
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Bonomo P; Greto D; Desideri I; Loi M; Di Cataldo V; Orlandi E; Iacovelli NA; Becherini C; Visani L; Salvestrini V; Mariotti M; Livi L
Oral Oncol; 2019 Jun; 93():1-7. PubMed ID: 31109688
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiotherapy for Recurrent Unresectable Head and Neck Cancers.
Strom T; Wishka C; Caudell JJ
Cancer Control; 2016 Jan; 23(1):6-11. PubMed ID: 27009451
[TBL] [Abstract][Full Text] [Related]
14. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N; Fumet JD; Limagne E; Thibaudin M; Hervieu A; Hennequin A; Zanetta S; Dalens L; Fourrier T; Galland L; Jacob P; Bertaut A; Rederstorff E; Chevalier C; Ghirardi S; Gilbert E; Khoukaz A; Martin E; Nicolet C; Quivrin M; Thibouw D; Vulquin N; Truc G; Rouffiac M; Ghiringhelli F; Mirjolet C
BMC Cancer; 2023 Nov; 23(1):1080. PubMed ID: 37946136
[TBL] [Abstract][Full Text] [Related]
16. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
17. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer.
Vempati P; Halthore AN; Teckie S; Rana Z; Gogineni E; Antone J; Zhang H; Marrero M; Beadle K; Frank DK; Aziz M; Paul D; Ghaly M
Radiat Oncol; 2020 Dec; 15(1):278. PubMed ID: 33308265
[TBL] [Abstract][Full Text] [Related]
19. HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial.
Elbers JBW; Gunsch PA; Debets R; Keereweer S; van Meerten E; Zindler J; van Norden Y; Hoogeman MS; Verduijn GM; Kroesen M; Nout RA
BMC Cancer; 2023 Jun; 23(1):541. PubMed ID: 37312053
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
